RSV Neutralizing Antibodies Following Nirsevimab and Palivizumab Dosing
This exploratory analysis from the phase 2/3 MEDLEY trial describes RSV neutralizing antibody levels associated with nirsevimab relative to palivizumab, the previous standard of care.